Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ:CVKD
Want to see CVKD full AI Analyst Report?
Top Page
Cadrenal Therapeutics, Inc.
(NASDAQ:CVKD)
Select Model
Select Model
Rating:42Neutral
Price Target:
$5.50
▲(5.36% Upside)
Action:ReiteratedDate:04/01/26
The score is primarily held down by weak financial performance (no revenue, widening losses, and accelerating cash burn with declining equity) and bearish technical trends (price below all key moving averages with negative MACD). Corporate events provide some offset via near-term funding and positive preclinical updates, but dilution risk tempers the benefit; valuation signals provide limited support given the lack of meaningful earnings/dividend metrics.
Positive Factors
Distinct mechanism: 12-LOX inhibitor
CAD-1005’s first-in-class 12-LOX mechanism provides durable differentiation versus standard anticoagulants and scarce direct competitors. A unique MOA can support durable intellectual property, make later-line superiority claims in registration trials, and broaden indication optionality across inflammatory cardiometabolic niches.
Negative Factors
No revenue and widening losses
The company lacks an operating revenue base and is generating larger net losses year-over-year, signaling the business remains pre-revenue and highly dependent on external capital. Over the medium term, this weakens self-funding ability and increases execution risk for clinical programs absent durable partner funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Distinct mechanism: 12-LOX inhibitor
CAD-1005’s first-in-class 12-LOX mechanism provides durable differentiation versus standard anticoagulants and scarce direct competitors. A unique MOA can support durable intellectual property, make later-line superiority claims in registration trials, and broaden indication optionality across inflammatory cardiometabolic niches.
Read all positive factors
Cadrenal Therapeutics, Inc. (CVKD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$13.86M
Dividend YieldN/A
Average Volume (3M)57.36K
Price to Earnings (P/E)―
Beta (1Y)1.06
Revenue GrowthN/A
EPS Growth-9.80%
CountryUS
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.37
Shares Outstanding2,506,817
10 Day Avg. Volume57,981
30 Day Avg. Volume57,363
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)4.94
Price to Sales (P/S)0.00
P/FCF Ratio-1.07
Enterprise Value/Market Cap0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.65K
Enterprise Value/Ebitda-0.73
Forecast
1Y Price Target
$29.00Price Target Upside455.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-4.92
Revenue Forecast (FY)N/A
Cadrenal Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in...
How the Company Makes Money
null...
Cadrenal Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
14
Very Negative
| Breakdown | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -1.88K | 0.00 | -1.27K |
| EBITDA | -13.46M | -10.65M | -8.34M | -6.61M |
| Net Income | -13.24M | -10.65M | -8.36M | -6.71M |
Balance Sheet | ||||
| Total Assets | 4.33M | 10.12M | 8.52M | 778.17K |
| Cash, Cash Equivalents and Short-Term Investments | 4.01M | 10.02M | 8.40M | 32.59K |
| Total Debt | 0.00 | 0.00 | 21.35K | 640.71K |
| Total Liabilities | 1.59M | 2.68M | 826.88K | 6.33M |
| Stockholders Equity | 2.74M | 7.44M | 7.69M | -5.55M |
Cash Flow | ||||
| Free Cash Flow | -12.60M | -7.36M | -3.53M | -1.20M |
| Operating Cash Flow | -12.60M | -7.36M | -3.53M | -1.20M |
| Investing Cash Flow | -5.10K | -6.54K | -3.25K | -2.28K |
| Financing Cash Flow | 6.60M | 8.98M | 11.90M | 1.24M |
Cadrenal Therapeutics, Inc. Technical Analysis
Neutral
5.22
Price Trends
6.26
Negative
7.28
Negative
9.95
Negative
Market Momentum
-0.48
Negative
45.77
Neutral
57.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CVKD, the sentiment is Neutral. The current price of 5.22 is above the 20-day moving average (MA) of 5.06, below the 50-day MA of 6.26, and below the 200-day MA of 9.95, indicating a neutral trend. The MACD of -0.48 indicates Negative momentum. The RSI at 45.77 is Neutral, neither overbought nor oversold. The STOCH value of 57.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CVKD.
Cadrenal Therapeutics, Inc. Risk Analysis
Cadrenal Therapeutics, Inc. disclosed 80 risk factors in its most recent earnings report. Cadrenal Therapeutics, Inc. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cadrenal Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $30.87M | -16.10 | 322.94% | ― | ― | ― | |
43 Neutral | $15.86M | -0.72 | -364.96% | ― | -48.74% | 89.18% | |
42 Neutral | $13.86M | -1.02 | -333.32% | ― | ― | -9.80% | |
42 Neutral | $5.14M | -1.49 | -92.74% | ― | 280.77% | 32.82% |
* Healthcare Sector Average
CVKD
Cadrenal Therapeutics, Inc.
5.50
-11.86
-68.32%
DARE
Daré Bioscience
2.11
-0.78
-26.99%
HIND
Vyome Holdings
2.21
-33.98
-93.89%
CLGN
Collplant Holdings
0.42
-1.79
-81.18%
LNAI
Lunai Bioworks
0.31
-3.33
-91.48%
TAOX
Tao Synergies
5.19
2.75
112.70%
Cadrenal Therapeutics, Inc. Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Cadrenal Therapeutics Enters Warrant Inducement Financing Agreement
Positive
Apr 1, 2026
On March 31, 2026, Cadrenal Therapeutics entered into a warrant inducement agreement with a warrant holder from its November 4, 2024 private placement, leading the holder to exercise existing warrants for 571,430 shares at a reduced price of $4.50...
Business Operations and StrategyProduct-Related Announcements
Cadrenal Highlights CAD-1005 Preclinical Data in Metabolic Disease
Positive
Mar 12, 2026
On March 12, 2026, Cadrenal Therapeutics highlighted new preclinical research on CAD-1005, a first-in-class 12-LOX inhibitor, showing its potential to address inflammatory complications of obesity and Type 2 diabetes. In animal models, oral CAD-10...
Business Operations and Strategy
Cadrenal Highlights Mixed Phase 2 Results for CAD-1005
Neutral
Feb 24, 2026
On February 24, 2026, Cadrenal Therapeutics reported results from a randomized, blinded, placebo-controlled Phase 2 trial of CAD-1005 in patients with heparin-induced thrombocytopenia, which concluded in December 2025 after transfer of the program...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.